NLRP3 and neoplasm: After 36 h of regorafenib or 5‐FU treatment, over 30% of NLRP3‐high expressing tumour cells exhibited marked pyroptotic morphologies, including nuclear pyknosis, cellular swelling and membrane blebbing, whereas only approximately 2% of NLRP3‐low expressing cells displayed similar morphological changes (Figures 1F and S2B).